Navigation Links
Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
Date:7/21/2009

PRINCETON, N.J. and SAN DIEGO, July 22 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two Phase I pharmacokinetic studies for TAK-652, an investigational compound being developed for the treatment of HIV. These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing. Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations. "These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO.

These data were presented at the 5th International Conference on HIV Pathogenesis, Treatment and Prevention, held July 19-23, 2009 in Cape Town, South Africa. Both poster presentations can be viewed at www.tobiratherapeutics.com.

About Tobira Therapeutics Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

    Contact:
    Antoinette Bobbitt, Tobira Therapeutics Inc.
    abobbitt@tobiratherapeutics.com
    Tel: 609-897-1102

www.tobiratherapeutics.com


'/>"/>
SOURCE Tobira Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Tobira Therapeutics Inc. Announces Senior Management Team
2. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
3. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... YORK , March 30, 2017 ... to Agenus Inc. (NASDAQ: AGEN), Intrexon Corp. (NYSE: XON), ... (NASDAQ: CXRX ). According an article on ... to "Overweight" from "Market Weight" on Tuesday, March 21 st , ... simply registering for free at: ...
(Date:3/29/2017)... KING OF PRUSSIA, Pa. , March 29, 2017 ... access to care, which is why CSL Behring awards ... advocacy work of rare disease patient groups. These groups ... patients, voices are heard on Capitol Hill and in ... current funding cycle, the community-based grant was awarded to ...
(Date:3/29/2017)... COLORADO SPRINGS, CO , March 29, 2017 /PRNewswire/ - Last year,s ... who support kratom are not the only efforts active to generate ... that substitute opiate based pharmaceutical drugs in the healthcare market place. ... Earlier this ... U.S. based developer and distributor of pharmaceutical and nutritional products, announced ...
(Date:3/29/2017)... ... , ... ComplianceOnline, the leading governance, risk and compliance advisory network with over ... 2017 venue and speaker lineup. The Summit will take place on June 8 and ... Parker House Hotel, which is located at 60 School Street, Boston, MA will be ...
Breaking Biology Technology:
(Date:3/7/2017)... LAKE CITY , March 7, 2017   ... that help top global companies identify the best talent, ... as Chief Sales Officer (CSO) and Diana ... Kucer,s appointments round out a seasoned executive team poised to ... and beyond, building on a year of record bookings ...
(Date:3/2/2017)... -- Summary This report provides all the information ... and activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ...
(Date:3/2/2017)... -- Who risk to be deprived of its imprint ... https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG CONFRONT ... sensors using capacitive technology represent a fast growing market, ... an increase of 360% of the number of fingerprint ... sensor market between 2014 and 2017 (source : N+1 ...
Breaking Biology News(10 mins):